Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia (NCT00304447)
The purpose of this study is to evaluate the effect of corticosteroids on the frequency and severity of the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) infusion-related adverse events, to evaluate the effect of corticosteroids on the efficacy of gemtuzumab ozogamicin (Mylotarg®) induced complete response (CR) and complete response with incomplete platelet recovery (CRp) at one-month post treatment.
This trial is sponsored by Pfizer/Wyeth-Ayerst Laboratories. 
- Condition: Acute Myelocytic Leukemia (AML)
- Phase: VI
- Estimated Enrollment: 30
- Start: April 2002
- Estimated Completion: January 2004
- Last verified: July 2009
Last Editorial review: July 22, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.